One of the most successful approaches to develop new small molecule therapeutics has been to start from a validated druggable protein target. However, only a small subset of potentially druggable targets has attracted significant research and development resources. The Illuminating the Druggable Genome (IDG) project develops resources to catalyze the development of likely targetable, yet currently understudied prospective drug targets. A central component of the IDG program is a comprehensive knowledge resource of the druggable genome. Results: As part of that effort, we have been developing a framework to integrate, navigate, and analyze drug discovery data based on formalized and standardized classifications and annotations of druggable protein targets, the Drug Target Ontology (DTO). DTO was constructed by extensive curation and consolidation of various resources. DTO classifies the four major drug target protein families, GPCRs, kinases, ion channels and nuclear receptors, based on phylogenecity, function, target development level, disease association, tissue expression, chemical ligand and substrate characteristics, and target-family specific characteristics. The formal ontology was built using a new software tool to auto-generate most axioms from a database while also supporting manual knowledge acquisition. A modular, hierarchical implementation facilitates development and maintenance and makes use of various external ontologies, thus integrating the DTO into the ecosystem of biomedical ontologies. As a formal OWL-DL ontology, DTO contains asserted and inferred axioms. Modeling data from the Library of Integrated Network-based Cellular Signatures (LINCS) program illustrates the potential of DTO for contextual data integration and nuanced definition of important drug target data. DTO has been implemented in the IDG user interface Portal, Pharos and the TIN-X explorer of protein target disease relationships.
INTRODUCTION
The development and approval of novel small molecule therapeutics (drugs) is highly complex and exceedingly resource intensive, being estimated at over one billion dollars for a new FDA approved drug. The primary reason for attrition in clinical trials is the lack of efficacy, which has been associated with poor or biased target selection [1] . Although the drug target mechanism of action is not required for FDA approval, a target-based mechanistic understanding of diseases and drug action is highly desirable and a preferred approach of drug development in the pharmaceutical industry. Following the advent of the Human Genome, several research groups in academia as well as industry have focused on "the druggable genome" i.e. the subsets of genes in the human genome that express proteins which have the ability to bind drug-like small molecules [2] . The researchers have estimated the number of druggable targets ranging from few hundred to several thousands [3] . Furthermore, it has been suggested by several analyses that only a small fraction of likely relevant druggable targets are extensively studied, leaving a potentially huge treasure trove of promising, yet understudied ("dark") drug targets to be explored by pharmaceutical companies and academic drug discovery researchers. Not only is there ambiguity about the number of the druggable targets, but there is also a need of systematic characterization and annotation of the druggable genome. A few research groups have made efforts to address these issues and have indeed developed several useful resources, e.g. IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb/IUPHAR) [4] , PANTHER [5] , Therapeutic Target Database (TTD) [6] , Potential Drug Target Database (PDTD) [7] , etc., covering important aspects of the drug targets. However, to the best of our knowledge and surprise, a publically available structured knowledge resource of drug target classifications and relevant annotations for the most important protein families, one that allows facilitates querying, data integration, re-use, and analysis does not currently exist. Content in the above-mentioned databases is scattered and in some cases inconsistent and duplicated, complicating data integration and analysis.
The Illuminating the Druggable Genome (IDG) project (http://targetcentral.ws/) has the goal to identify and prioritize new prospective drug targets among likely targetable, yet currently poorly or not at all annotated proteins; and by doing so to catalyze the development of novel drugs with new mechanism of action. Data compiled and analyzed by the IDG Knowledge Management Center (IDG-KMC) shows that the globally marketed drugs stem from only 3% of the human proteome. These results also suggest that the substantial knowledge deficit for understudied drug targets may be due to an uneven distribution of information and resources [8] .
In the context of the IDG program we have been developing the Drug Target Ontology (DTO).
Formal ontologies have been quite useful to facilitate harmonization, integration, and analysis of diverse data in the biomedical and other domains . DTO integrates and harmonizes knowledge of the most important druggable protein families: kinases, GPCRs, ion channels and nuclear hormone receptors. DTO content was extracted from many information sources and extensively curated from the literature including detailed hierarchical classifications of proteins and genes, tissue localization, disease association, drug target development level, protein domain information, ligands, substrates, and other types of relevant information. DTO is aimed towards the drug discovery and clinical communities and was built to align with other ontologies including BioAssay Ontology (BAO) [9] [10] [11] and GPCR Ontology [12] . By providing a semantic framework of diverse information related to druggable proteins, DTO facilitates the otherwise challenging integration and formal linking of heterogeneous and diverse data important for drug discovery.
DTO is particularly relevant for "big data" systems-level models of diseases and drug action and the era of precision medicine. The long-term goal of DTO is to provide such an integrative framework and to populate the ontology with this information as a community resource. Here we describe the development, content, architecture, modeling and use of the DTO. Specifically, we used DTO and BAO to describe and model assays and results data from the Library of Integrated Network-based Cellular Signatures (LINCS) program to facilitate data integration and analysis.
DTO has already been implemented in end-user software tools to facilitate the browsing [11] and navigation of drug target data (DC Cannon et al, Bioinformatics 2017, submitted).
Methods

Drug Target data curation and classification
DTO places special emphasis on the four protein families that are central to the NIH IDG initiative: [14] , UniProt and several linked databases therein. The classification is based on both the phylogenetic and functional information. Additional information regarding the gating mechanism (voltage gated, ligand gated, etc.), transported ions, protein structural and topological information has also been captured and included as separate annotations.
Moreover, the transported ions, viz. chloride, sodium, etc. have been mapped to the "Chemical entity" of the ChEBI reference database [15] .
GPCR classification:
GPCRs have been classified based on phylogenetic, functional and the endogenous ligand information. The primary classification included class, group, family, and
subfamily. Most of the information has been taken from the GPCR.org classification and had been updated using various sources e.g. IUPHAR [4] , ChEMBL, UniProt and also from our earlier GPCR ontology [12] . Furthermore, the information for the specific endogenous ligands for each protein has been extracted from IUPHAR and has been integrated with the classification. The information about the GPCR ligand and ligand type (lipid, peptide, etc.) has also been included and has been mapped manually to the "Chemical entity" of the ChEBI reference database.
Nuclear receptor classification: This information has been adopted directly from IUPHAR.
External DTO modules and mapping: Proteins mapped to UniProt. Genes were classified identical to proteins (above) and mapped to Entrez gene. The external modules incorporated into DTO were extracted from the Disease Ontology (DOID) [16] , BRENDA Tissue Ontology (BTO) [17] , UBERON [18] , the ontology of Chemical Entities of Biological Interest (ChEBI) [19] , and
Protein Ontology (PRO) [20] . Data about over 1000 cell lines from the LINCS project [21] were integrated and mapped to diseases and tissues. Gene/protein-disease [22] and protein-tissue associations [23] were obtained from the JensenLab at Novo Nordisk Foundation Center for Protein Research. Mapping between UBERON and BRENDA to integrate the tissue associations of cell lines and proteins was retrieved from the NCBO BioPortal [24, 25] and manually crosschecked. Target Development Level (TDL) were obtained from TCRD and included as separate annotation for all protein families.
Drug Target Ontology (DTO) development
Ontology modeling: While curators stored all classification and annotation data into various spreadsheets, ontologists semi-manually created the ontological model to link the metadata obtained from those spreadsheets, and to create the descriptive logic axioms to define ontology classes. Finalizing and optimizing the ontology model or design pattern required iterative processes of intensive discussions, modeling refinement, voting, and approval among domain experts, data curators, IT developers, and ontologists. Once the most fit ontology model was chosen, this piece of modeling was used as template for a java tool (described below) to generate all the OWL files by using above mentioned data annotation spreadsheets as input.
Modularization approach: DTO uses an improved modular architecture based on the modular architecture designed and implemented for BAO, described in [9] . The modularization strategy indirectly) from module and/or vocabulary files [9] . The external third party ontologies were extracted using the OWL API or OntoFox [26] .
OntoJOG tool: To streamline the building process, a Java tool (OntoJOG) was developed to automatically create the OWL module files, vocabulary files as components of the whole ontology.
OntoJOG takes a flat CSV or TSV data file and loads it as a table either into a temporary SQLite database or a permanent MySQL database. This table is then used as a reference for creating and generating the OWL files as well as several relationship tables. The relationship tables and the final OWL files are generated based on a CSV mapping file that generates the commands for the OntoJOG to perform and the various options for those commands. The commands from the mapping file are read in two passes to ensure everything is added correctly. In the first pass all classes and their annotations are inserted into the relationship tables and are assigned IDs as necessary, and in the second pass all axioms and relationships between classes are created. After this process is completed an optional reparenting phase is executed before each module of the ontology is generated into its own OWL vocabulary files with an accompanying module file containing the relationships for the given vocabulary files.
Finally, the ontology was thoroughly reviewed, tested and validated by developers, domain experts, and users in the IDG KMC.
DTO Visualization
Data visualization is important, especially with the increasing complexity of the data. Ontology visualization, correspondingly, has an appealing potential to help to browse and comprehend the structures of ontologies. A number of ontology visualization tools have been developed and applied as information retrieval aids, such as OntoGraf, OWLViz as part of the Ontology development tool Protégé, and OntoSphere3D [27] among others. Further, studies and reviews on different visualization tools, e.g. [28, 29] and [30] , have been published by comparing each tool's performances. Preference of visualization models depend on the type and query context of the visualized network, also on users' needs.
Data-Driven Document (D3) is a relatively novel representation-transparent and dynamic
approach to visualize data on the web. It is a modern interactive visualization tool available as a JavaScript library [28] . By selectively binding input data to arbitrary document elements, D3.js enables direct inspection and manipulation of a native representation. The D3.js JavaScript library gained popularity as a generic framework based on widely accepted web standards such as SVG, JavaScript, HTML5 and CSS.
Consequently, we use the D3.js library for the interactive visualization of our DTO as part of the Neo4J graphical database solution.
DTO and BAO integration to model LINCS data
The Library of Network-Based Cellular Signatures (LINCS) Program has a systems biology focus.
This project has been generating a reference "library" of molecular signatures, such as changes in gene expression and other cellular phenotypes that occur when cells are exposed to a variety of perturbing agents, and computational tools for data integration, access, and analysis. One of the License. DTO will also be published at the NCBO BioPortal.
Results
In what follows, the italic font represents terms, classes, relations, or axioms used in the ontology.
Drug Targets definition and classification
Different communities have been using the term "drug target" ambiguously with no formal generally accepted definition. The DTO project develops a formal semantic model for drug targets including various related information such as protein, gene, protein domain, protein structure, binding site, small molecule drug, mechanism of action, protein tissue localization, disease associations, and many other types of information.
The IDG project defines 'drug target' as "a native (gene product) protein or protein complex that physically interacts with a therapeutic drug (with some binding affinity) and where this physical interaction is (at least partially) the cause of a (detectable) clinical effect". DTO adopted this definition as a DTO class: drug target, which is a subclass of protein.
DTO provides various asserted and inferred hierarchies to classify drug targets. Here we describe the most relevant ones.
Target Development Level (TDL)
The IDG classified proteins into four levels with respect to the depth of investigation from a clinical, biological and chemical standpoint (http://targetcentral.ws/ ): 1) Tclin are proteins targeted by approved drugs as they exert their mode of action [3] . The Tclin proteins are designated drug targets under the context of IDG;
2) Tchem are proteins that can specifically be manipulated with small molecules better than bioactivity cutoff values (30 nM for kinases, 100 nM for GPCRs and NRs, 10 uM for ICs, and 1 uM for other target classes), which lack approved small molecule or biologic drugs. In some cases, targets have been manually migrated to Tchem through human curation, based on small molecule activities from sources other than ChEMBL or Drug Central;
3) Tbio are proteins that do not satisfy the Tclin or Tchem criteria, which are annotated with a Gene Ontology Molecular Function or Biological Process with an Experimental Evidence code, or targets with confirmed OMIM phenotype(s), or do not satisfy the Tdark criteria detailed in 4); 4) Tdark refers to proteins that have been described at the sequence level and have very few associated studies. They do not have any known drug or small molecule activities that satisfy the activity thresholds detailed in 2), lack OMIM and GO terms that would match Tbio criteria, and meet at least two of the following conditions:
 A PubMed text-mining score < 5 (19)  The 62 Non-protein kinases are categorized in 5 Groups depending upon the substrate that are phosphorylated by these proteins. These 5 groups are further sub-categorized in 25 families and 7
subfamilies. There are two kinases that haven't been categorized yet in any of the above types or groups.
The 
Disease-and tissue-based classification
Target-disease associations and tissue expressions were obtained from the DISEASES [22] and TISSUES [23] databases (see methods). Examples of such classifications are available as inferences in DTO (see below section 3.3.2).
Additional annotations and classifications
In addition to the phylogenetic classification of the proteins, there are several relevant properties associated with them as additional annotations. For example, there are 46 PKs that have been annotated as Pseudokinases. For Ion channels, important properties, like transporter protein type, transported ion(s), Gating mechanism, etc. have been associated with the individual proteins. The
Gating mechanism refers to the information regarding the factors that control the opening and closing of the ion channels. The important mechanisms include Voltage-gated, Ligand-gated, Temperature-gated, Mechanically-gated, etc. Similarly, for the GPCRs, the additional information whether any receptor has a known endogenous ligand or is currently "orphan" is mapped with the individual proteins. Current version of DTO has approximately 255 receptors that have information available regarding the endogenous ligands.
The analysis of Drug target protein classification along with such relevant information associated through separate annotations may lead to interesting inferences.
Chemical classifications
Known GPCR ligands and IC transported ions were categorized by chemical properties and mapped to ChEBI (see methods). For example, depending upon their chemical structure and properties, these known endogenous ligands for GPCRs have been categorized in seven types, namely, amine, amino acid, carboxylic acid, lipid, peptide, nucleoside and nucleotide. Similarly, the ions transported by the ion channel proteins and ion types (anion/cation) have been mapped to ChEBI. These annotations together with mappings of substrates and ligands to the proteins enable inferred classification of the proteins based on their chemical properties (see below). DTO is implemented in OWL2-DL to enable further classification by inference reasoning and SPARQL queries. The current version of IDG contains > 13,000 classes and > 220,000 axioms.
DTO ontology implementation and modeling
Drug discovery target knowledge model of the DTO
The DTO contains 827 GPCRs, 572 kinase, 342 ion channels (ICs), and 48 NRs.
Modular implementation of the DTO combining auto-generated and expert axioms
In DTO, each of the four drug target families has two vocabulary files of gene and protein respectively, some DTO native categories were created as one separate vocabulary file. Other This approach significantly simplifies the maintenance of the ontology contents, especially when the ontology is large in size. If the gene list or protein list needs to be updated, only the vocabulary file and the specific module file need to be updated instead of the whole ontology. In addition, external and internal resources are managed separately. In addition, this modularization approach facilitates automated content updates from external resources, including axioms generated using the above-mentioned Java tool OntoJOG without the need to re-generate manually axiomized domain knowledge, which is very resource intensive, by simply separating them into two layers.
DTO to infer biologically and chemically relevant target classes
Chemically relevant target classes inferred by DTO
In addition to detailed asserted target classifications, DTO incorporates various other annotations including GPCR endogenous ligands for GPCRs, transported ions for ICs, gating mechanism for ICs, Pseudokinases. Endogenous GPCR ligands were manually mapped to ChEBI and classified by chemical category such as amine, lipid, peptide, etc. As ligands relate to receptor properties, GPCRs are typically classified based on their ligands; however, the ligand-based classification is orthogonal to the classification based on class A, B, C, adhesion, etc. and it changes as new ligands are deorphanized.
In DTO we therefore infer the ligand-based receptor, for example aminergic GPCR, lipidergic GPCR, peptidic GPCR, and orphan GPCR, which are of particular interest, by defining their logical equivalent as follows:
aminergic GPCR ≡ GPCR and ('binds molecular entity' some Amine);
lipidergic GPCR ≡ GPCR and ('binds molecular entity' some Lipid); peptidic GPCR ≡ GPCR and ('binds molecular entity' some Peptide); orphan GPCR ≡ GPCR and (not ('binds molecular entity' some 'GPCR ligand')).
An example for 5-hydroxytryptamine receptor is shown in figure 4 ; the receptor is inferred as aminergic receptor based on its endogenous ligand. DTO has classified 39 aminergic GPCR, 37 lipidergic GPCR, 119 peptide GPCR and 582 orphan GPCR.
Disease relevant target classes inferred by DTO
In a similar way, we categorize important disease targets by inference based on the protein -disease association, which are modeled as 'strong', 'at least some', or 'at least weak' evidence using subsumption. For example, DTO uses the following hierarchical relations to declare the relation between a protein and the associated disease extracted from the DISEASES database.
has associated disease with at least weak evidence from DISEASES -has associated disease with at least some evidence from DISEASES -has associated disease with strong evidence from DISEASES
In the DISEASES database, the associated disease and protein are measured by a Z-Score [22] . In DTO, the "at least weak evidence" is translated as a Z-Score between zero and 2.4; the "some evidence" is translated as a Z-Score between 2.5 and 3.5; and the "strong evidence" is translated as a Z-Score between 3.6 and 5.
This allows querying or inferring proteins for a disease of interest by evidence. Diseases related targets were defined using following axioms:
Putative infectious disease targets ≡ Protein and ('has associated disease with at least some evidence from DISEASES' some 'disease of metabolism');
Putative infectious disease targets ≡ Protein and ('has associated disease with at least some evidence from DISEASES' some 'disease by infectious agent');
Putative mental health disease targets≡ Protein and ('has associated disease with at least some evidence from DISEASES' some 'developmental disorder of mental health') DTO has classified 45 metabolic disease targets, 32 mental health disease targets, and 11 infectious disease targets.
Modeling and integration of Kinase data from the LINCS program
The Library of Network-Based Cellular Signatures (LINCS, http://lincsproject.org/) program has a systems biology focus. This project has been generating a reference "library" of molecular signatures, such as changes in gene expression and other cellular phenotypes that occur when cells are exposed to a variety of perturbing agents. The project also builds computational tools for data integration, access, and analysis. Dimensions of LINCS signatures include the biological model system (cell type), the perturbation (e.g. small molecules) and the assays that generate diverse phenotypic profiles. LINCS aims to create a full data matrix by coordinating cell types and perturbations as well as informatics and analytics tools. We have processed various LINCS datasets, which are available at the LINCS Data Portal (http://lincsportal.ccs.miami.edu/). LINCS data standards [21] are the foundation of LINCS data integration and analysis and we have previously illustrated how integrated LINCS data can be used to characterize drug action [33] ;
among those, KINOME-wide drug profiling datasets.
We have annotated the KINOMEscan domains data generated from HMS LICS KINOMEScan dataset. The annotation includes domains descriptions, names, gene symbols, phosphorylation status, and mutations. To integrate this information into DTO, we built a kinase domain module following the modularization approach mentioned in section 2.2.
We started with an example scenario given by domain expert shown below:
-ABL1 is a tyrosine-protein kinase with UNIPROT id P00519 (human). The sequence itself is 1131 AA long. In this scenario, there are four major ontological considerations or relations need to be decided when building an ontology module ( Figure 5 ).
Kinase domain and kinase protein
DTO use "has part" relation to link the kinase protein and kinase domain, which reflects the biological reality that kinase domain is a partial protein.
Kinase domain variations: mutated kinase domain and phosphorylated kinase domain
Mutated kinase domain relates to its wild type kinase domain by simply using "is mutated format of" relation. Both of phosphorylated and nonphosphorylated forms of a kinase domain are child of a kinase domain from which they were modified to current phosphorylation variation forms. Since the KINOMEscan assay cannot provide the specific phosphorylation position information, the definition of a phosphorylated form of a kinase domain, either mutated or wild, is generally constituted using an ad-hoc axiom: has part some "phosphorylated residue". Note that "phosphorylated residue" (MOD_00696) is an external class imported from Protein Modification Ontology (MOD).
Pfam domain mapping to kinase domain and its variations
DTO data curators/domain experts have mapped all the kinase domains (including their variations)
to Pfam families using sequence level data. This information was captured by using "map to pfam domain" relation, which links a kinase domain to a pfam domain. 
Kinase gatekeeper and mutated amino acid residues
The kinase gatekeeper position is an important recognition and selectivity element for small molecular binding. One of the mechanisms by which cancers evade kinase drug molecular therapy is by mutation of key amino acids in the kinase domain. Often the gatekeeper is mutated. Located in the ATP binding pocket of protein kinases, the gatekeeper residue has been shown to control sensitivity to a wide range of small molecule inhibitors. Kinases that possess a small side chain at this position (Thr, Ala, or Gly) are readily targeted by structurally diverse classes of inhibitors, whereas kinases that possess a larger residue at this position are broadly resistant [34] .
DTO defines a "gatekeeper role" to capture any residue that is annotated as a gatekeeper. In above scenario, the THR 74 within the ABL1 Kinase domain, in other words, the Threonine amino acid located in the 74 th residue of the ABL1 Kinase amino acid sequence, is identified as a gatekeeper by the data curator/domain expert. DTO defines a term: THR74 in ABL1 Kinase domain, and gives an axiom to this term "has role some gatekeeper role". With an equivalence definition of term -25 -"gatekeeper residue" as anything that satisfied the condition of "has role some gatekeeper role", DTO can group all the gatekeeper residues in this KINOMEscan dataset ( Figure 6 ). Figure 6 . Protégé screen shot shows the inferred subclasses of gatekeeper residue.
Integration of DTO in software applications
DTO Visualization
The drug target ontology consists of > 13,000 classes and > 122,000 links. Our visualization has two options: a) a static pure ontology viewer starting with the top-level concepts featured by a collapsible tree layout (mainly for browsing concepts) and b) a dynamic search and view page where a search-by-class user interface is combined with a collapsible force layout for a deeper exploration. Figure 7 shows an excerpt of an interactive visualization of the DTO. Users can search for classes, alter the visualization by showing siblings, zoom in/out, and alter the figure by moving classes within the graph for better visualization.
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Pharos: The IDG Web Portal
Pharos is the front-end Web Portal of the IDG project (https://pharos.nih.gov). Pharos was designed and built to encourage "serendipitous browsing" of a wide range of protein drug target information curated and aggregated from a multitude of resources [11] . 
Tin-X: Target Importance and Novelty Explorer
TIN-X is a specialized, user-friendly Web-based tool to explore the relationship between proteins 
CONCLUSION AND DISCUSSION
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The IDG program is a systematic effort to prioritize understudied, yet likely druggable protein targets for the development of chemical probes and drug discovery entry points [3] . Two kinds of druggability exists: (1) the structural druggability: ability of a protein to bind a (small molecule) drug, and (2) We have illustrated how DTO, BAO and other ontologies are used to describe, categorize and integrate kinase data generated in the LINCS; the ontologies are being used in the LDP (http://lincsportal.ccs.miami.edu/). As we develop DTO and other resources, we will facilitate the otherwise challenging integration and formal linking of biochemical and cell-based assays, phenotypes, disease models, omics data, drug targets and drug poly-pharmacology, binding sites, kinetics and many other processes, functions and qualities that are at the core of drug discovery.
In the Era of "big data", systems-level models for diseases and drug action and personalized medicine, it is a critical requirement to harmonize and integrate these various sources of information. DTO is designed to be easily extensible and integrative to other recourses, especially applying the modularization approach. Several drug target related new resources have been developed, such as the ChEMBL Drug Target Slim [35] , where GO annotations are available for drug targets in ChEMBL. Protein Ontology recently enhanced the protein annotation with pathway information and phosphorylation sites information [36] . Comprehensive FDA proved drug and target information is available in [3] . DTO will incorporate all these newly developed resources, and support an integrative drug discovery data portal as a community resource.
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